A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia

Completed

Conditions studied: Aplastic Anemia

In brief

The aim of this study was to investigate the safety, tolerability, and effectiveness of eltrombopag in combination with immunosuppressive therapy (IST) in real world practice in pediatric patients with severe aplastic anemia (sAA) in Korea. The study used data over a 6-month period extracted from patients' medical charts (electronic medical records) starting from the initiation of eltrombopag treatment.

Key facts

Study ID

NCT07415083

Run by

Novartis Pharmaceuticals

People needed

13

Starts

2023-06-21

Expected to finish

2025-02-25

Last updated by the study team

2026-02-19

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female pediatric patients aged ≥2 years and <18 years at the time of initiating eltrombopag and IST treatment.
• Subjects diagnosed with sAA and treated with eltrombopag in combination with IST as first-line therapy, based on the physician's decision in accordance with locally approved prescribing information at the time of data collection.
• Subjects whose analytical index date (start date of eltrombopag administration) was at least 6 months prior to the data extraction date.

You may not qualify if…

• None.

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.